...
首页> 外文期刊>Cellular immunology >Key genes and proteins involved in CTCM-reducing microvascular endothelial cell permeability induced by SLT-IIv using gene chips and DIGE
【24h】

Key genes and proteins involved in CTCM-reducing microvascular endothelial cell permeability induced by SLT-IIv using gene chips and DIGE

机译:使用基因芯片和DIGE参与SLT-IIv诱导CTCM降低微血管内皮细胞通透性的关键基因和蛋白质

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

An Affymetrix mouse genome array and differential in-gel electrophoresis (DIGE) techniques were used to investigate the pharmacological mechanisms of a mixture of herbs, designated CTCM, a compound of traditional Chinese medicine, for the treatment of increased permeability in mouse intestinal microvascular endothelial cells (MIMECs) induced by the Shiga-like toxin type II variant (SLT-IIv). MIMECs were challenged with 10μg/ml SLT-IIv for 12. h and then treated with CTCM at a concentration of 200μg/ml for 12. h. Total RNA and proteins from each treatment group were extracted from cultured MIMECs for analysis by the Affymetrix GeneChip? Mouse Genome 430 2.0 microarray and DIGE. The results obtained demonstrated that there were one genes downregulated and one genes upregulated, one protein downregulated and four proteins upregulated in the SLT-IIv group compared to the control group. In the CTCM group, four genes were upregulated, three genes were downregulated, a single protein was downregulated and a single protein was upregulated when compared to the control group. When the CTCM-treated group was compared to the SLT-IIv group, expression of one gene was found to be increased, and all other genes were decreased, with five proteins downregulated. Analysis of the data suggested that CTCM specifically and effectively reduced microvascular endothelial cell permeability to SLT-IIv in the treatment of pig edema disease. In the CTCM-treated group, hspa9 expression was increased in both gene chip and DIGE analysis, so it may be a key protein in reducing cell permeability and utilized in medical treatments.
机译:Affymetrix小鼠基因组阵列和差异凝胶电泳(DIGE)技术用于研究草药混合物(称为CTCM)的药理机制,该混合物被称为中药化合物,用于治疗小鼠肠道微血管内皮细胞通透性增加(MIMECs)由志贺样毒素II型变体(SLT-IIv)诱导。用10μg/ ml SLT-IIv攻击MIMEC 12小时,然后以200μg/ ml的浓度用CTCM处理12h。从培养的MIMEC中提取每个治疗组的总RNA和蛋白质,以通过Affymetrix GeneChip?进行分析。小鼠基因组430 2.0微阵列和DIGE。获得的结果表明,与对照组相比,SLT-IIv组中有一个基因被下调,一个基因被上调,一个蛋白被下调,四个蛋白被上调。与对照组相比,在CTCM组中,四个基因被上调,三个基因被下调,单个蛋白被下调,单个蛋白被上调。当将CTCM治疗组与SLT-IIv组进行比较时,发现一个基因的表达增加,而所有其他基因的表达减少,其中五个蛋白被下调。对数据的分析表明,CTCM在治疗猪水肿病中特异性和有效地降低了微血管内皮细胞对SLT-IIv的通透性。在CTCM治疗组中,hspa9表达在基因芯片和DIGE分析中均增加,因此它可能是降低细胞通透性的关键蛋白,可用于医学治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号